The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Duvakitug was well tolerated and safety was consistent with the induction study
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
